Navigation Links
FUISZ Announces Advances in Devices and Solid Dosage Form
Date:7/1/2010

MIAMI, July 1 /PRNewswire/ -- FUISZ today announced two medical technology advances.

First, FUISZ announced that it has received a notice of issuance from the United States Patent and Trademark Office for patent claims that cover a direct connection between prescribing physicians and blood analysis devices.  The invention allows for the health care provider to set the parameters of allowable analyte levels for each patient and enables simple notifications for any variance out of a pre-determined range. Joseph Fuisz, managing member of FUISZ stated, "These patent claims represents a quantum leap in the use of portable blood analyzers to provide a higher level of care for patients while reducing burdens on health care providers. We are in discussions with the blood analyzer industry for the licensing of this technology."

FUISZ also announced that it has filed a new patent in the field of solid oral Bioactive dosage forms. This novel system works to enhance or retard drug absorption.  It is particularly well suited to buccal, sublinqual and other forms of mucosal delivery including nano particles.  Joseph Fuisz commented, "This innovation can be readily adapted for use with existing products to improve control of drug absorption.  It will be particularly well received in the opiate market where controlling relative absorption of opiates and agonists is so critical.  This technology draws upon our deep knowledge of quick dissolve dosage forms and applies that knowledge in a broad manner to all solid dosage forms."

FUISZ is a family owned company. Fuisz principals Richard Fuisz, M.D. and Joseph Fuisz, Esq. are named inventors on or owners of hundreds of patents and patent applications. These patents span several fields: drug delivery, quick dissolve dosage forms including quick dissolve tablets, thin films, slow dissolve sheets, conventional oral dosage units, opiate abuse resistance, women's health, electronic mail, e-commerce, and tobacco. The company is based in Miami, Florida. www.fuisz.com.


'/>"/>
SOURCE FUISZ
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Fuisz Tobacco Announces Clinical Study Results for Fuisz Tobacco Sheet Strip; Super Enhanced Bioavailability of Nicotine From Its Tobacco Sheet Strip Supports Efficacy of Low Dose Tobacco Product
2. Fuisz Pharma Announces Novel Anti Abuse System for Opiates
3. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
4. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
5. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
6. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
7. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
8. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
9. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
10. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
11. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... DALLAS , April 19, 2017 /PRNewswire/ ... that the first patients in Nashville ... in the Lower Esophageal Sphincter Stimulation for GERD (LESS ... device designed to provide long-term reflux control by restoring ... GERD affects nearly 65 million people in ...
(Date:4/19/2017)... , April 19, 2017 ... stimulate an immune response in pets such as ... products are of various types such as Attenuated ... Toxoid Vaccines, DNA Vaccines and Recombinant Vaccines. Attenuated ... as virus or bacteria, which have been weakend ...
(Date:4/19/2017)... Calif. , April 19, 2017  SARES•REGIS ... buildings it is developing at Conejo Spectrum Business ... , to Atara Biotherapeutics, Inc. , a ... severe and life-threatening diseases that have been underserved ... allogeneic T-cell therapies for cancer, autoimmune and infectious ...
Breaking Medicine Technology:
(Date:4/25/2017)... ... April 25, 2017 , ... A recent report from the ... for the 2015-16 school year across Wisconsin’s public schools, charter schools, and private ... patterns in student test score performance, the report’s limited analyses fail to provide ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... procedure that achieves results in a fraction of the time as traditional braces ... with Significance Dental Specialists, now offers this revolutionary treatment with or without a ...
(Date:4/25/2017)... ... 2017 , ... Back Pain Centers of America (BPC), which connects ... in their area, announces the launch of a new and proprietary customer relationship management ... for reputable physicians to help them with back or neck pain and helps to ...
(Date:4/25/2017)... Santa Clara, CA (PRWEB) , ... April 25, ... ... technology, announces the addition of predictive analytics to its patient care management module. ... therapy compliance even before a patient has been initiated on continuous positive airway ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... animal healthcare products, is introducing Flexadin UCII, part of the EQUISTRO line, at ... and joint health in horses at the immunologic level. , The scientifically-developed Flexadin ...
Breaking Medicine News(10 mins):